Skip to main content

Table 4 Post-treatment according to EGFR mutation status as second line between Del-19and L858R (n = 78)

From: Differential efficacy of cisplatin plus pemetrexed between L858R and Del-19 in advanced EGFR-mutant non-squamous non-small cell lung cancer

Post-treatment Del-19 (n = 36) L858R (n = 42)
No.of patients % No.of patients %
Not received 0 0% 0 0%
Received
 Platinum doublet therapy 0 0% 0 0%
 Single-agent chemotherapy 1 2.8% 1 2.4%
 EGFR-TKI therapy 32 88.9% 38 90.5%
 Other molecular target drug therapy 2 5.5% 2 4.7%
 Immunotherapy 0 0% 0 0%
 Other 1 2.8% 0 0%
During first line chemotherapy 0 0% 1 2.4%
  1. EGFR-TKI epidermal growth factor receptor-tyrosine kinase inhibitor